RepliCel’s Chief Medical Officer to Present at 21st European Academy of Dermatology & Venereology Congress
VANCOUVER, BC – September, 26, 2012 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”) (OTCBB:REPCF) today announces that Dr. Rolf Hoffmann, RepliCel’s Chief Medical Officer, will be presenting at the 21st European Academy of Dermatology and Venereology Congress in Prague, Czech Republic on Thursday, September 27th from 3:00 PM to 6:00 PM local time. During this focused session on hair and scalp diseases, Dr. Hoffmann will explain the background of the invention and will be discussing results from the Company’s first- in-man Phase I clinical trials using the RepliCel® treatment as a potential solution for androgenetic alopecia. For more information please visit www.eadvprague2012.org.
About RepliCel Life Sciences Inc.
The Company has developed RepliCel™, a patented natural hair cell replication technology that has the potential to become the world’s first, minimally invasive solution for androgenetic alopecia and general hair loss in men and women. RepliCel™ is based on autologous cell implantation technology that replicates a patient’s hair cells from their own healthy hair follicles and, when reintroduced into areas of hair loss, initiates natural hair regeneration. The Company is currently conducting first-in-man clinical trials. Additional information on RepliCel is available at www.replicel.com.
For more information please contact:
Director of Communications
Notice Regarding Forward Looking Statements
This press release contains forward-looking statements, including but not limited to: states that the Company will complete a Phase II clinical trial and that RepliCelTM has the potential to become the world’s first, minimally invasive solution for androgenetic alopecia and general hair loss in men and women. These statements are only predictions and involve known and unknown risks which may cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking statements. These risks and uncertainties include: whether the Company can obtain regulatory approval for its planned Phase II clinical trial; that negative results may result from the Company’s clinical trials; the effects of government regulation on the Company’s business; risks associated with the Company’s ability to obtain and protect rights to its intellectual property; risks and uncertainties associated with the Company’s ability to raise additional capital to carry out its planned activities; and other factors beyond the Company’s control. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity or performance. Readers should consult all of the information set forth herein and should also refer to the risk factor disclosure outlined in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2011, and other periodic reports filed from time-to-time with the Securities and Exchange Commission on Edgar at www.sec.gov and with the British Columbia Securities Commission on SEDAR at www.sedar.com.
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.
THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.